Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

How I Treat in Brief: Managing Post-Thrombotic Syndrome

Anat Rabinovich, MD, of Soroka University Medical Center at the Ben-Gurion University of the Negev in Israel and Susan R. Kahn, MD, MSc, of...
WIB_icon

Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?

Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...

No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...

Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...
WIB_icon

Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...

Rivaroxaban Fails to Prevent VTE and VTE-Related Mortality After Hospital Discharge

Patients hospitalized for an acute medical illness are at an increased risk for developing venous thromboembolism (VTE) in the six weeks after discharge, but...

American Society of Hematology’s Guidelines for Venous Thromboembolism and von Willebrand Disease

In 2018, the American Society of Hematology (ASH) has continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists...

Researchers Define Long-Term Outcomes of Cancer-Associated Thrombosis

Patients diagnosed with cancer-associated thrombosis (CAT) remain at a high risk for recurrent venous thromboembolism (VTE), bleeding, and death – even while on therapeutic...

Tumor Site, D-Dimer Markers Predict VTE Risk in Patients With Cancer

Venous thromboembolism (VTE) is a common complication of cancer, with the risk of developing VTE varying greatly depending on several patient and disease factors....
WIB_icon

No Benefit, but Excess Toxicity, With Rivaroxaban for Patients With High-Risk Antiphospholipid Syndrome

Rivaroxaban and other direct oral anticoagulants are used as an alternative to warfarin for the prevention of thromboembolism, but data do not support routine...
Advertisement

Current Issue

December 2018, Volume 4, Issue 14

This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.